Uncategorized

Tratamiento pionero para prevenir el rechazo en trasplantes.

julio 20, 2021

Cilastatin: a potential treatment strategy against COVID-19.

noviembre 1, 2020 DOI: 10.1093/ckj/sfaa193

María Ángeles González-Nicolás, Cristian González-Guerrero, Verónica Astrid Pérez-Fernández, Alberto Lázaro. Clinical Kidney Journal, Volume 13, Issue 5, October 2020, Pages 903–905. DOI: 10.1093/ckj/sfaa193 Based on the preclinical evidence of kidney and lung protection in the context of endotoxemia as presented in this letter. We propose that cilastatin should be studied in clinical trials as a potential therapy for COVID-19.… Leer más »Cilastatin: a potential treatment strategy against COVID-19.

Platelet and immune characteristics of immune thrombocy-topaenia patients non-responsive to therapy reveal severeimmune dysregulation.

enero 16, 2020 DOI: 10.1111/bjh.16459

Elena Monzón Manzano, María Teresa Álvarez Román, Raúl Justo Sanz, Hosvan y Fernández Bello, Diana Hernández, Mónica Martín Salces, Larissa Valor, Isabel Rivas Pollmar, Nora V. Butta1 and Víctor Jiménez Yuste. British Society for Haematology and John Wiley & Sons LtdBritish Journal of Haematology, 2020, 189, 943–953 – 16 january 2020. DOI: 10.1111/bjh.16459 Abstract Multifactorial mechanisms… Leer más »Platelet and immune characteristics of immune thrombocy-topaenia patients non-responsive to therapy reveal severeimmune dysregulation.